JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data ...

RIT's Title IX Office is a neutral entity, dedicated to maintaining a safe and inclusive environment that is free from harassment and discrimination against any member of the RIT Community on the ...